Frontlight ResearchEarly access
Taking people in FrancePhase 4
Testing daridorexant for sleep problems in people with memory decline or mild Alzheimer disease
Tests daridorexant for insomnia in adults with mild memory decline or mild Alzheimer disease.
Key facts
- Who runs it
- Centre Hospitalier Universitaire De Montpellier
- Where
- Montpellier Cedex 5, FranceSee the site
- Trial code
- Registry title
- Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease.
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 62 people, planned
- Started
- 14 Dec 2023
- Expected to end
- 13 Mar 2028
- Type of study
- Interventional
- Record updated
- 19 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for outpatients aged 60 to 85 with early Alzheimer disease or mild cognitive impairment who also have insomnia. It tests daridorexant 50 mg for sleep time.
- Age
- 60 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Mild cognitive impairment or early, mild-to-moderate Alzheimer disease, with MMSE 12 to 26 and CDR 0.5 to 2. Insomnia with total sleep time under 6 hours, at least 3 nights a week.
- Earlier treatment
- Anticholinesterase drugs, memantine, some antidepressants, neuroleptics and level 2 pain drugs are allowed if the dose was stable for at least 3 months. Hypnotics and level 3 pain drugs are not allowed.
- Biomarker or test result
- Positive CSF Aβ42 and/or positive plasma biomarker, and hippocampal and/or temporal atrophy on MRI. Baseline sleep study (PSG) must show total sleep time under 6 hours and wake after sleep onset over 1 hour.
Main reasons for not taking part
- Patients who depend heavily on caregivers
- Current psychiatric disorder (DSM-5)
- Moderate or severe liver failure
- Severe sleep-related breathing disorder (over 30 apnea/hypopnea episodes per hour)
- History of narcolepsy or cataplexy, or of drug or alcohol abuse
The registry criteria, word for word
Show all 28 criteriaShow less
Who can take part
- Age [60-85] years old
- Outpatients
- Pre-screening: • Complaints of dissatisfaction with sleep quantity or quality, despite adequate opportunity for sleep, at least 3 nights per week and for at least 3 months, and • Total sleep time causes clinically significant distress or impairment in daytime functioning, and • Total sleep time estimated by interview was below 6 hours, on at least 3 nights per week and for at least 1 month before screening
- Baseline PSG (at randomization) assessed TST < 6 hours and WASO > 1 hour
- Diagnosis of MCI and AD patients at an early stage according to the NIA diagnosis criteria (core clinical criteria for MCI, positive CSF Aβ42 and/or positive plasma biomarker, and neuronal injury (hippocampal and/or temporal atrophy by MRI))
- MMSE from 12 to 26
- Clinical Dementia Rating CDR from 0.5 to 2
- Use of CNS-active medications is permitted provided the dose has been stable for at least 3 months, including: anticholinesterase drugs (rivastigmine, donepezil, galantamine) or memantine, antidepressants SSRI (e.g. fluoxetine, sertraline, paroxetine…), SNRI (e.g. venlafaxine, duloxetine), neuroleptics (e.g. clozapine, olanzapine, aripiprazole...) or drug for pain level 2 (codeine, tramadol)
Who cannot take part
- Use of hypnotics (benzodiazepines, zolpidem, zopiclone) or drug for pain level 3 (morphine and derivatives)
- Forbidden and restricted concomitant medications: • Concomitant CNS-depressant medicinal products • CYP3A4 inhibitors • CYP3A4 inducers
- Participation in another clinical trial or administration of an investigational product
- History of diagnosed and characterized psychiatric disorders (DSM-5), cured or stabilized (with or without the same treatment for at least 3 months) and excluding any current characterized psychiatric disorder (DSM-5), the diagnosis of which is established by a psychiatrist trained in geriatric psychiatry
- Moderate and severe liver failure
- PSG baseline evidence of significant/severe sleep-related breathing disorder (defined as >30 apnea/hypopnea episodes per hour)
- Hypersensitivity to the active substance or to any of the excipients listed in the Summary of Product Characteristics (SmPC)
- Failure to obtain written informed consent after a reflection period
- History of narcolepsy and/or cataplexy
- History of drug or alcohol abuse or addiction
- Patients significantly dependent on caregivers
- Treatments interfering with sleep-wake patterns
- Protected population according to articles of the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship/curatorship)
- Subjects not covered by public health insurance
- Institutionalized patients
- Analphabetism or subjects unable to read or/and write
- Patients unable to perform the neuropsychological tests
- Patients unable to complete the study instruments (sleep diary)
- Planned longer stay outside the region that prevents compliance with the visit schedule
- Patients who cannot be followed up for at least 2 months
Where in France
- University Hospital Of MontpellierMontpellier Cedex 5, FranceTaking people
About the trial
What the trial wants to find out
To evaluate the efficacy of oral administration of daridorexant 50 mg on the total sleep time (TST) duration as assessed via polysomnography from baseline to post-baseline, in outpatients with MCI and mild-to-moderate AD, with insomnia disorder.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease.
- Plain-language title
- Testing daridorexant for sleep problems in people with memory decline or mild Alzheimer diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 19 June 2026